UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~August~~November 1913, 2025

_________________________

GoHealth, Inc.

(Exact name of registrant as specified in its charter)

_________________________

Delaware	001-39390	~~001~~85-~~39390~~0563805	~~85-0563805~~
(State or other jurisdiction of incorporation)	(Commission File Number)	(~~Commission~~I.R.S. ~~File~~Employer ~~Number~~Identification No.)	~~(I.R.S. Employer Identification No.)~~
222 W Merchandise Mart Plaza, Suite 1750			60654
Chicago,	Illinois
(Address of principal executive offices)			(Zip Code)


222 W Merchandise Mart Plaza, Suite 1750		60654
Chicago,	Illinois
(Address of principal executive offices)		(Zip Code)

(312) 386-8200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

_________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange
on which registered

Class A Common Stock,
$0.0001 par value per share

GOCO

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.02. ~~Departure~~Results of ~~Directors~~Operations orand ~~Certain~~Financial ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Condition.

~~Director~~On ~~Appointments~~November 13, 2025, the Company issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

OnThe ~~August~~information ~~19,~~furnished ~~2025,~~pursuant ~~the~~to ~~Board~~this ofItem ~~Directors~~2.02 ~~(the~~and ~~“Board”)~~Exhibit of99.1 ~~GoHealth,~~attached ~~Inc.~~hereto ~~(the~~shall ~~“Company”)~~not ~~appointed~~be ~~Mark~~deemed ~~Weinsten~~filed asfor apurposes ~~Class~~of IISection ~~director~~18 of the ~~Board,~~Securities ~~effective~~Exchange ~~immediately.~~Act ~~Mr.~~of ~~Weinsten~~1934, ~~currently~~as ~~serves~~amended as(the a“Exchange ~~managing~~Act”) ~~director~~or inotherwise ~~BRG~~subject ~~Corporate~~to ~~Finance~~the ~~where,~~liabilities ~~among~~of ~~other~~that ~~services~~section, henor ~~develops~~shall ~~business~~it ~~plans~~be ~~and~~deemed ~~restructuring~~incorporated ~~strategies;~~by ~~evaluates~~reference ~~and~~in ~~negotiates~~any ~~strategic~~filing ~~transactions;~~under ~~and~~the ~~implements~~Securities ~~revenue~~Act ~~and~~of ~~liquidity~~1933, ~~improvement~~as ~~programs.~~amended ~~Mr.~~(the ~~Weinsten~~“Securities ~~will~~Act”), ~~serve~~or ~~with a term expiring at~~ the ~~Company’s~~Exchange ~~annual~~Act ~~meeting~~except ofas ~~stockholders~~shall to be ~~held~~expressly inset ~~2028~~forth ~~and~~by ~~until~~specific ~~his~~reference ~~successor~~in issuch ~~duly elected and qualified or his earlier death, disqualification, resignation or removal~~filing.

Mr. Weinsten will be entitled to receive a monthly cash retainer of $25,000 for his service on the Board, which will be pro-rated for his first partial month of service. He will also be reimbursed for certain expenses incurred by him in connection with his service on the Board.

On August 19, 2025, the Board also appointed Bao Truong as a Class III director of the Board, effective immediately. Mr. Truong currently serves as a senior managing director of Centerbridge Partners, L.P. (“Centerbridge”) where he oversees investments in a range of sectors across the firm’s private equity and credit business. Mr. Truong will serve with a term expiring at the Company’s annual meeting of stockholders to be held in 2026, and until his successor is duly elected and qualified or his earlier death, disqualification, resignation or removal. Mr. Truong was appointed to the Transformation Committee of the Board, the Compensation Committee of the Board and the Nominating and Corporate Governance Committee of the Board.

As a Centerbridge employee, Mr. Truong will not receive compensation for service on the Board.

In connection with their appointments, the Company and each of Messrs. Weinsten and Truong have entered into the Company’s standard indemnification agreement for directors.

Messrs. Weinsten and Truong were nominated to the Board as designees of Centerbridge pursuant to the terms of the Stockholders Agreement, dated as of July 15, 2020, by and among the Company and the persons and entities listed on the schedules attached thereto (the “Stockholders Agreement”).

Except for any transactions involving Centerbridge described in the Company’s proxy statement relating to its 2025 annual meeting of stockholders, there are no transactions between the Company and Mr. Truong that would be required to be reported under Item 404(a) of Regulation S-K. With respect to Mr. Weinsten, there are no transactions between the Company and Mr. Weinsten that would be required to be reported under Item 404(a) of Regulation S-K.

Director Resignations

On August 19, 2025, Jeremy W. Gelber and Abhiraj Modi, members of the Board, resigned from the Board. Messrs. Gelber and Modi were nominated to the Board as designees of Centerbridge pursuant to the terms of the Stockholders Agreement. Their resignations were not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Item 9.01. Financial Statements and Exhibits.

The following exhibits are included herewith:

Exhibit Number						Description
99.1						Press Release issued by GoHealth, Inc. on November 13, 2025.
104						Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		GOHEALTH, INC.
Date:	~~August~~November 1913, 2025	By:	/s/ Brendan Shanahan
			Brendan ShanahanChief Financial Officer(Principal Financial Officer)

Filing Compare · GoHealth, Inc.